Brainstorm Cell Therapeutics Inc. Share Price & Technical Analysis
BCLI · $0.68 (-4.23%)
Healthcare / Biotechnology
$0.68
-4.23%
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modula…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
17% return in May, -3% avg return in past 3 year May month.
29% return in 2026, -48% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 17% | 29% | -33% | 17% | – | – | – | – | – | – | – | 29% |
| 25 | -22% | -11% | -19% | 8% | -15% | 0% | -36% | 14% | -12% | -14% | 0% | 0% | -108% |
| 24 | 27% | -2% | 56% | -37% | 11% | -35% | 0% | -10% | -19% | -44% | -11% | 35% | -29% |
| 23 | 9% | 23% | 48% | -13% | -3% | -28% | -10% | -10% | -88% | -27% | 91% | 0% | -8% |
| 22 | -22% | -3% | 9% | -10% | -1% | -8% | -7% | 40% | 21% | -20% | -54% | -2% | -57% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$7.28M
P/E ratio
—
52W high
$1.33
52W low
$0.46
Volume
610
Beta
0.21
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Brainstorm Cell Therapeutics Inc. share price today?
- Brainstorm Cell Therapeutics Inc. (BCLI) last traded around $0.68 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BCLI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BCLI. Download the app for real-time alerts.
- How can I analyze Brainstorm Cell Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.